Molecular profiling as a novel tool to predict response to interferon-α2 in MPNs: The proof of concept in early myelofibrosis

High-risk mutations are associated with poor response to interferon-α2. Early treatment with interferon-α2 is recommended in patients who have early myelofibrosis without high-risk mutations. See referenced original article on pages 000-000, this issue.

http://ift.tt/2rva0Ef